4D Molecular Therapeutics(FDMT)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $15.22 (+3.68%), 시가총액 $0.48B, 52주 최저~최고 $3.42 ~ $12.27.
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geograph
4D Molecular Therapeutics의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
4D Molecular Therapeutics의 현재 주가는 $15.22 (+3.68%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
4D Molecular Therapeutics의 시가총액은 약 $0.48B입니다.
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic